Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Neuroprotective Effect of IND1316, an Indole-Based AMPK Activator, in Animal Models of Huntington Disease

  • Vela, Marta
  • Sanchis, Ana
  • Bono-Yagüe, José
  • Cumella, José
  • Lagartera, Laura
  • Pérez, Concepción
  • Priego, Eva María
  • Campos, Angela
  • Sanz, Pascual
  • Vázquez-Manrique, Rafael P.
  • Castro, Ana
  • García-Gimeno, María Adelaida|||0000-0002-6483-3912
[EN] Aggregation of mutant huntingtin, because of an expanded polyglutamine track, underlies the cause of neurodegeneration in Huntington disease (HD). However, it remains unclear how some alterations at the cellular level lead to specific structural changes in HD brains. In this context, the neuroprotective effect of the activation of AMP-activated protein kinase (AMPK) appears to be a determinant factor in several neurodegenerative diseases, including HD. In the present work, we describe a series of indole-derived compounds able to activate AMPK at the cellular level. By using animal models of HD (both worms and mice), we demonstrate the in vivo efficacy of one of these compounds (IND1316), confirming that it can reduce the neuropathological symptoms of this disease. Taken together, in vivo results and in silico studies of druggability, allow us to suggest that IND1316 could be considered as a promising new lead compound for the treatment of HD and other central nervous system diseases in which the activation of AMPK results in neuroprotection., We thank the CGC, which is funded by the NIH Office of Research Infrastructure Programs (P40 OD010440), for providing worm strains. RPVM is a Miguel Servet type II researcher (CPII16/00004) funded by Instituto de Salud Carlos III (ISCIII, Madrid, Spain). Grants from the ISCIII (PI17/00011 and PI20/00114), the Spanish Ministerio de Ciencia Innovacion y Universidades (RTI2018-095544-B-I00) and the Fundacio Marato de TV3 (Ref.: 559) were used to perform this work . All grants from ISCIII are co-financed by the European Development Regional Fund "A way to achieve Europe" (ERDF). Funds from the Fundacion Ramon Areces were also used (CIVP19S8119). J.B.Y . holds a grant by the Generalitat Valenciana and the European Social Fund (ACIF/2019/249). R.V.M. received an Ayuda Miguel Gil grant to RPVM (VII Convocatoria Ayudas a la Investigacion MHER, 2019, cofinanced by Colegio Oficial de Farmaceuticos de Sevilla and Fundacion Cajasol). R.V.M. has also received funds from the Asociacion Valenciana de Enfermedad de Huntington (AVAEH) . This work was also supported by an intramural ACCI2016 grant from the CIBERER-ISCiii to A.C., P.S., and R.V.M.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Metformin to treat Huntington disease: A pleiotropic drug against a multi-system disorder

  • Trujillo-Del Río, Cristina
  • Tortajada-Pérez, J.
  • Gómez-Escribano, A.P.
  • Casterá, F.
  • Peiró, C.
  • Millán, J.M.
  • Herrero, M.J.
  • Vázquez-Manrique, R.P.
[EN] Huntington disease (HD) is a neurodegenerative disorder produced by an expansion of CAG repeats in the HTT gene. Patients of HD show involuntary movements, cognitive decline and psychiatric impairment. People carrying abnormally long expansions of CAGs (more than 35 CAG repeats) produce mutant huntingtin (mHtt), which encodes tracks of polyglutamines (polyQs). These polyQs make the protein prone to aggregate and cause it to acquire a toxic gain of function. Principally affecting the frontal cortex and the striatum, mHtt disrupts many cellular functions. In addition, this protein is expressed ubiquitously, and some reports show that many other cell types are affected by the toxicity of mHtt. Several studies reported that metformin, a widely-used anti-diabetic drug, is neuroprotective in models of HD. Here, we provide a review of the benefits of this substance to treat HD. Metformin is a pleiotropic drug, modulating different targets such as AMPK, insulin signalling and many others. These molecules regulate autophagy, chaperone expression, and more, which in turn reduce mHtt toxicity. Moreover, metformin alters gut microbiome and its metabolic processes. The study of potential targets, interactions between the drug, host and microbiome, or genomic and pharmacogenomic approaches may allow us to design personalised medicine to treat HD., RPVM used grants (PI17/00011 and PI20/00114) funded by the Instituto de Salud Carlos III (ISCIII, Madrid, Spain). These grants are cofinanced by the European Development Regional Fund ''A way to achieve Europe'' (ERDF). Funds from the Fundacion Ramon Areces (CIVP19S8119) and from CIBERER (ACCI-2019-22) were also used. CTR holds a grant by the Generalitat Valenciana and the European Social Fund (ACIF/2020/366). CIBERER is an initiative developed by the Instituto de Salud Carlos III in cooperative and translational research on rare diseases. RVM received an Ayuda Miguel Gil grant (VII Convocatoria Ayudas a la Investigacion MEUHER, 2019, cofinanced by Colegio Oficial de Farmaceuticos de Sevilla and Fundacion Cajasol). RVM has also received funds from the Asociacion Valenciana de Enfermedad de Huntington (AVAEH).